1Cademy - Results from Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Concept

Results from Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Day 3: no difference in reduction in viral load between intervention and control arms (difference of 0.01, [95% CI 0.28, 0.29])
Day 7: no difference in reduction of viral load between intervention and control arms (difference of -0.07, [95% CI -.44, .29])
No reduction in risk of hospitalization: 7.1% in control versus 5.9% intervention (RR .75, [95% CI .32, 1.77])
No shortened duration of symptoms: 12 days in control versus 10 in intervention (log rank test for survival analysis p=0.38)